Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Mod Pathol Retrieve available abstracts of 41 articles: HTML format

Single Articles

October 2025
1. RAKHA EA, Tan PH, Van Bockstal MR, Allison KH, et al
   International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-low and Ultralow Categories.
   Mod Pathol. 2025 Oct 28:100925. doi: 10.1016/j.modpat.2025.100925.
   PubMed     Abstract available
   
   
   
2. KHOURY T, Zhan H, Huang X, Ghasemi F, et al
   Predicting the Probability of Residual Axillary Nodal Metastases in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
   Mod Pathol. 2025 Oct 1:100902. doi: 10.1016/j.modpat.2025.100902.
   PubMed     Abstract available
   
   
   
3. ANH NGUYEN TT, Zhang J, Iqbal J, Ahmed SS, et al
   Proposing New Criteria for Classification of Benign Fibroepithelial Lesions Based on Clinicopathologic Evaluations of 507 Cases with Clinical Outcome.
   Mod Pathol. 2025;38:100812.
   PubMed     Abstract available
   
   
   
4. BADVE S, White JS, Sapunar F, Thoele K, et al
   Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark.
   Mod Pathol. 2025;38:100813.
   PubMed     Abstract available
   
   
   September 2025
5. MORRAR D, Brogi E, Schwartz CJ, Pareja F, et al
   HER2-ultralow Breast Cancer: Incidence, Clinicopathologic Features and Need for Refined Scoring System.
   Mod Pathol. 2025 Sep 29:100901. doi: 10.1016/j.modpat.2025.100901.
   PubMed     Abstract available
   
   
   
6. FLORIS G, Djerroudi L, Zels G, De Schepper M, et al
   Pitfalls in the Histological Diagnosis of Morphologic Variants of Invasive Lobular Carcinoma of the Breast.
   Mod Pathol. 2025;38:100837.
   PubMed     Abstract available
   
   
   August 2025
7. SCHILDHAUS HU, Badve S, D'Arrigo C, Farshid G, et al
   A Global Ring Study: Concordance Between Ventana PATHWAY anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-low Breast Cancer.
   Mod Pathol. 2025 Aug 9:100867. doi: 10.1016/j.modpat.2025.100867.
   PubMed     Abstract available
   
   
   
8. HU Y, Jones D, Zhao W, Tozbikian G, et al
   Incidence, Clinicopathologic Features, and Follow-Up Results of human epidermal growth factor receptor-2-Ultralow Breast Carcinoma.
   Mod Pathol. 2025;38:100783.
   PubMed     Abstract available
   
   
   
9. MARKEY M, Kim J, Goldstein Z, Gerardin Y, et al
   Spatial Mapping of Gene Signatures in Hematoxylin and Eosin-Stained Images: A Proof of Concept for Interpretable Predictions Using Additive Multiple Instance Learning.
   Mod Pathol. 2025;38:100772.
   PubMed     Abstract available
   
   
   July 2025
10. STEEN S, Boissin C, Rantalainen M, Acs B, et al
    Histological grade has clinical validity in neoadjuvant treated breast cancer: A multicenter study.
    Mod Pathol. 2025 Jul 25:100850. doi: 10.1016/j.modpat.2025.100850.
    PubMed     Abstract available
    
    
    
11. SU Z, Guo Y, Wesolowski R, Tozbikian G, et al
    Computational Pathology for Accurate Prediction of Breast Cancer Recurrence: Development and Validation of a Deep Learning-based Tool.
    Mod Pathol. 2025 Jul 16:100847. doi: 10.1016/j.modpat.2025.100847.
    PubMed     Abstract available
    
    
    
12. DAI W, Navolotskaia O, Fine JL, Harinath L, et al
    Not All HER2-Positive Breast Cancers Are the Same: Intratumoral Heterogeneity, Low-Level HER2 Amplification, and Their Impact on Neoadjuvant Therapy Response.
    Mod Pathol. 2025;38:100785.
    PubMed     Abstract available
    
    
    
13. RUTLAND CD, Kingsley L, Wang A, Zdravkovic S, et al
    RNA In Situ Hybridization Detection of CRTC1/3::MAML2 Fusions and LINC00473 in Mucoepidermoid Carcinomas and Hidradenomas of Breast, Salivary Glands, and Skin.
    Mod Pathol. 2025;38:100756.
    PubMed     Abstract available
    
    
    May 2025
14. PONS L, Hernandez L, Urbizu A, Arnaldo L, et al
    Molecular Landscape, Genomic Shift and Prediction in the Neoadjuvant Setting of HER2 Positive Breast Cancer.
    Mod Pathol. 2025 May 6:100787. doi: 10.1016/j.modpat.2025.100787.
    PubMed     Abstract available
    
    
    
15. RAKHA EA, Quinn C, Raymond W, Allison KH, et al
    Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management.
    Mod Pathol. 2025;38:100734.
    PubMed     Abstract available
    
    
    
16. HAN R, Pareja F, Ross DS, Grabenstetter A, et al
    Frank Invasion in Tall Cell Carcinoma With Reversed Polarity of the Breast: Report of Two Cases.
    Mod Pathol. 2025;38:100714.
    PubMed     Abstract available
    
    
    April 2025
17. JIAO D, Dai H, Fei J, Wang D, et al
    Impact of Hormone Receptor Status and HER2 Expression on Neoadjuvant Targeted Therapy Response in HER2-Positive Breast Cancer: A Multicenter Retrospective Study.
    Mod Pathol. 2025 Apr 15:100778. doi: 10.1016/j.modpat.2025.100778.
    PubMed     Abstract available
    
    
    
18. ABUBAKAR M, Fan S, Klein A, Pfeiffer RM, et al
    Spatially-resolved Single-cell Morphometry of Benign Breast Disease Biopsy Images Uncovers Quantitative Cytomorphometric Features Predictive of Subsequent Invasive Breast Cancer Risk.
    Mod Pathol. 2025 Apr 8:100767. doi: 10.1016/j.modpat.2025.100767.
    PubMed     Abstract available
    
    
    
19. ATALLAH N, Makhlouf S, Li X, Zhang Y, et al
    Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay.
    Mod Pathol. 2025;38:100713.
    PubMed     Abstract available
    
    
    
20. FARSHID G, Armes J, Dessauvagie B, Gilhotra A, et al
    Independent Validation of a HER2-Low Focused Immunohistochemistry Scoring System for Enhanced Pathologist Precision and Consistency.
    Mod Pathol. 2025;38:100693.
    PubMed     Abstract available
    
    
    February 2025
21. CHA YJ, O'Connell CE, Calhoun BC, Felsheim BM, et al
    Genomic Characteristics Related to Histology-based Immune Features in Breast Cancer.
    Mod Pathol. 2025 Feb 14:100736. doi: 10.1016/j.modpat.2025.100736.
    PubMed     Abstract available
    
    
    
22. VAZQUEZ TP, Goncalves R, Gomes da Cunha JP, Silva Rivas FW, et al
    Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in patients receiving Neoadjuvant Chemotherapy for HR-Positive HER2-Negative Breast Cancer.
    Mod Pathol. 2025 Feb 7:100733. doi: 10.1016/j.modpat.2025.100733.
    PubMed     Abstract available
    
    
    January 2025
23. SHENASA E, He Y, Wang Z, Tu D, et al
    Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit.
    Mod Pathol. 2025 Jan 23:100718. doi: 10.1016/j.modpat.2025.100718.
    PubMed     Abstract available
    
    
    
24. YE Q, Law T, Klippel D, Albarracin C, et al
    Prospective and retrospective analysis of whole slide images of sentinel and targeted lymph node frozen sections in breast cancer.
    Mod Pathol. 2025 Jan 7:100708. doi: 10.1016/j.modpat.2025.100708.
    PubMed     Abstract available
    
    
    
25. LI Z, Hu Y, Jones D, Zhao W, et al
    Clinicopathologic Characteristics and Follow-Up Outcomes of Invasive Breast Carcinoma With Different Positive HER2 Fluorescence In Situ Hybridization Patterns: Experience From a Single Academic Institution.
    Mod Pathol. 2025;38:100637.
    PubMed     Abstract available
    
    
    December 2024
26. KAHILA MMH, Chesebro AL, Giess CS, Rhei E, et al
    Pathologic Features of Malignancies Presenting as Asymmetry on Mammography.
    Mod Pathol. 2024;37:100612.
    PubMed     Abstract available
    
    
    
27. YE J, Theparee T, Bean GR, Rutland CD, et al
    Targeted DNA Sequencing in Diagnosis of Malignant Phyllodes Tumors With Emphasis on Tumors With Keratin and p63 Expression.
    Mod Pathol. 2024;37:100593.
    PubMed     Abstract available
    
    
    November 2024
28. MI H, Varadhan R, Cimino-Mathews AM, Emens LA, et al
    Spatial Architecture of Single-cell and Vasculature in Tumor Microenvironment Predicts Clinical Outcomes in Triple-Negative Breast Cancer.
    Mod Pathol. 2024 Nov 8:100652. doi: 10.1016/j.modpat.2024.100652.
    PubMed     Abstract available
    
    
    
29. PABBA A, Zels G, De Schepper M, Geukens T, et al
    Stromal tumor infiltrating lymphocytes in hormone receptor positive/HER2 negative metastatic breast cancer.
    Mod Pathol. 2024 Nov 8:100650. doi: 10.1016/j.modpat.2024.100650.
    PubMed     Abstract available
    
    
    October 2024
30. DJERROUDI L, Bendali A, Fuhrmann L, Benoist C, et al
    E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma.
    Mod Pathol. 2024;37:100570.
    PubMed     Abstract available
    
    
    August 2024
31. GHANNAM SF, Makhlouf S, Alsaleem M, Rutland CS, et al
    The conflicting prognostic role of the stroma-ratio in breast cancer molecular subtypes.
    Mod Pathol. 2024 Aug 29:100607. doi: 10.1016/j.modpat.2024.100607.
    PubMed     Abstract available
    
    
    
32. SCHWARTZ CJ, Marra A, Selenica P, Gazzo A, et al
    RB1 Genetic Alterations in Estrogen Receptor-Positive Breast Carcinomas: Correlation With Neuroendocrine Differentiation.
    Mod Pathol. 2024;37:100541.
    PubMed     Abstract available
    
    
    July 2024
33. RAMMAL R, Goel K, Motanagh SA, Carter GJ, et al
    Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Mod Pathol. 2024;37:100517.
    PubMed     Abstract available
    
    
    June 2024
34. FARSHID G, Armes J, Dessauvagie B, Gilhotra A, et al
    Development and Validation of a HER2-Low Focused IHC Scoring System with High Inter-Observer Concordance The Australian HER2-low Breast Cancer Concordance Study.
    Mod Pathol. 2024 Jun 7:100535. doi: 10.1016/j.modpat.2024.100535.
    PubMed     Abstract available
    
    
    May 2024
35. INGEBRIKTSEN LM, Svanoe AA, Saele AKM, Humlevik ROC, et al
    Age-related clusters and favorable immune phenotypes in breast cancer of the young.
    Mod Pathol. 2024 May 27:100529. doi: 10.1016/j.modpat.2024.100529.
    PubMed     Abstract available
    
    
    
36. AJABNOOR R, Zhang G, Hu Y, Gao Y, et al
    Breast Cancer with HER2 IHC 2+ and Average HER2 Signals/Cell >/= 6 and HER2/CEP17 Ratio < 2: A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.
    Mod Pathol. 2024 May 27:100530. doi: 10.1016/j.modpat.2024.100530.
    PubMed     Abstract available
    
    
    
37. DJERROUDI L, El Sabeh-Ayoun A, Benoist C, Pierron G, et al
    Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
    Mod Pathol. 2024;37:100463.
    PubMed     Abstract available
    
    
    April 2024
38. DE SCHEPPER M, Koorman T, Richard F, Christgen M, et al
    Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the European Lobular Breast Cancer Consortium.
    Mod Pathol. 2024 Apr 17:100497. doi: 10.1016/j.modpat.2024.100497.
    PubMed     Abstract available
    
    
    
39. HARINATH L, Villatoro TM, Clark BZ, Fine JL, et al
    Upgrade Rates of Variant Lobular Carcinoma In Situ Compared to Classic Lobular Carcinoma In Situ Diagnosed in Core Needle Biopsies: A 10-Year Single Institution Retrospective Study.
    Mod Pathol. 2024;37:100462.
    PubMed     Abstract available
    
    
    February 2024
40. SHAFIQUE A, Gonzalez R, Pantanowitz L, Tan PH, et al
    A Preliminary Investigation into Search and Matching for Tumor Discrimination in World Health Organization Breast Taxonomy Using Deep Networks.
    Mod Pathol. 2024;37:100381.
    PubMed     Abstract available
    
    
    
41. DERAKHSHAN F, Da Cruz Paula A, Selenica P, da Silva EM, et al
    Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
    Mod Pathol. 2024;37:100375.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.